{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T20:42:42Z","timestamp":1774816962951,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.109073","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T05:43:27Z","timestamp":1658382207000},"page":"109073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting EZH2 prevents the occurrence and mitigates the development of Sj\u00f6gren's syndrome in mice"],"prefix":"10.1016","volume":"110","author":[{"given":"Shicong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109073_b0005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren's Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109073_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.109073_b0015","first-page":"354","article-title":"The Diagnosis and Treatment of Sjogren's Syndrome","volume":"114","author":"Stefanski","year":"2017","journal-title":"Dtsch. Arztebl. Int."},{"issue":"Suppl 126","key":"10.1016\/j.intimp.2022.109073_b0020","first-page":"3","article-title":"One year in review 2020: pathogenesis of primary Sjogren's syndrome","volume":"38","author":"Bombardieri","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109073_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9093057","article-title":"Contributions of Major Cell Populations to Sjogren's Syndrome","volume":"9","author":"Witas","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2022.109073_b0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sjogren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109073_b0035","doi-asserted-by":"crossref","first-page":"8101503","DOI":"10.1155\/2019\/8101503","article-title":"Sjogren's Syndrome: Animal Models, Etiology, Pathogenesis, Clinical Subtypes, and Diagnosis","volume":"2019","author":"Shen","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2022.109073_b0040","article-title":"T cells in primary Sjogren's syndrome: targets for early intervention","author":"Verstappen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 126","key":"10.1016\/j.intimp.2022.109073_b0045","first-page":"315","article-title":"Pathogenesis of primary Sjogren's syndrome beyond B lymphocytes","volume":"38","author":"Fasano","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109073_b0050","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjogren's Syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2022.109073_b0055","doi-asserted-by":"crossref","unstructured":"O. Liu, J. Xu, F. Wang, W. Jin, P. Zanvit, D. Wang, et al., Adipose-mesenchymal stromal cells suppress experimental Sjogren syndrome by IL-33-driven expansion of ST2(+) regulatory T cells, iScience 24 (2021) 102446. https:\/\/doi.org\/10.1016\/j.isci.2021.102446.","DOI":"10.1016\/j.isci.2021.102446"},{"key":"10.1016\/j.intimp.2022.109073_b0060","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/annrheumdis-2020-217481","article-title":"Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjogren syndrome refractory to rituximab alone","volume":"79","author":"Chevalier","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.109073_b0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2022.109073_b0070","doi-asserted-by":"crossref","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sjogren's syndrome: Old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.intimp.2022.109073_b0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/jpet.107.135798","article-title":"The protein kinase A pathway contributes to Hg2+-induced alterations in phosphorylation and subcellular distribution of occludin associated with increased tight junction permeability of salivary epithelial cell monolayers","volume":"326","author":"Kawedia","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2022.109073_b0080","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","article-title":"The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells","volume":"39","author":"Tumes","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2022.109073_b0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","article-title":"The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation","volume":"42","author":"DuPage","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.109073_b0090","doi-asserted-by":"crossref","first-page":"102404","DOI":"10.1016\/j.jaut.2020.102404","article-title":"EZH2 deficiency attenuates Treg differentiation in rheumatoid arthritis","volume":"108","author":"Xiao","year":"2020","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.intimp.2022.109073_b0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41423-019-0219-z","article-title":"The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109073_b0100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4049\/jimmunol.1701470","article-title":"EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production","volume":"200","author":"Guo","year":"2018","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109073_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"B\u00e9guelin","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2022.109073_b0110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/JLB.1MA0321-155RR","article-title":"Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function","volume":"110","author":"Yu","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2022.109073_b0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/cdd.2014.142","article-title":"Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-kappaB pathway","volume":"22","author":"Zhang","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2022.109073_b0120","doi-asserted-by":"crossref","first-page":"173076","DOI":"10.1016\/j.ejphar.2020.173076","article-title":"GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1alpha in human peritoneal mesothelial cells treated with high glucose","volume":"880","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109073_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10176-2","article-title":"Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.109073_b0130","doi-asserted-by":"crossref","unstructured":"S. Lee, D. C. Woo, J. Kang, M. Ra, K. H. Kim, S.R. Lee, et al., The Role of the Histone Methyltransferase EZH2 in Liver Inflammation and Fibrosis in STAM NASH Mice, Biology (Basel) (2020) 9. https:\/\/doi.org\/10.3390\/biology9050093.","DOI":"10.3390\/biology9050093"},{"issue":"10","key":"10.1016\/j.intimp.2022.109073_b0135","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.40931","article-title":"Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL\/lpr Mice","volume":"71","author":"Rohraff","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2022.109073_b0140","doi-asserted-by":"crossref","first-page":"653989","DOI":"10.3389\/fimmu.2021.653989","article-title":"EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB\/NZW F1 Mice","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109073_b0145","doi-asserted-by":"crossref","first-page":"681941","DOI":"10.3389\/fimmu.2021.681941","article-title":"The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjogren's Syndrome","volume":"12","author":"Verstappen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109073_b0150","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2174\/1381612821666150316120024","article-title":"Mouse Models of Primary Sjogren's Syndrome","volume":"21","author":"Park","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.intimp.2022.109073_b0155","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.2792","article-title":"Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome","volume":"45","author":"Lessard","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2022.109073_b0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clim.2017.04.005","article-title":"Sjogren's syndrome: Clinical aspects","volume":"182","author":"Vivino","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109073_b0165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/PPA.S132751","article-title":"Sjogren's syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from Short Form 36 questionnaire and a meta-analysis","volume":"11","author":"Zhang","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.intimp.2022.109073_b0170","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sjogren's syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2022.109073_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.01.024","article-title":"Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren's signature correlating with disease activity and glandular inflammation","volume":"137","author":"Mingueneau","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109073_b0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.40676","article-title":"Tissue-Resident Memory CD8+ T Cells Acting as Mediators of Salivary Gland Damage in a Murine Model of Sjogren's Syndrome","volume":"71","author":"Gao","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2022.109073_b0185","doi-asserted-by":"crossref","unstructured":"T.B. Miranda, C.C. Cortez, C.B. Yoo, G. Liang, M. Abe, T.K. Kelly, et al., DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation, Mol, Cancer Ther. 8 (2009) 1579\u20131588. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0013.","DOI":"10.1158\/1535-7163.MCT-09-0013"},{"issue":"1","key":"10.1016\/j.intimp.2022.109073_b0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ni.3313","article-title":"Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction","volume":"17","author":"Zhao","year":"2016","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109073_b0195","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1476-5586(03)80032-5","article-title":"Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene","volume":"5","author":"Raaphorst","year":"2003","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.intimp.2022.109073_b0200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/1354750X.2015.1118537","article-title":"Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients","volume":"21","author":"Liu","year":"2016","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/j.intimp.2022.109073_b0205","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0561-z","article-title":"STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer","volume":"15","author":"Pan","year":"2016","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2022.109073_b0210","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjc.6602531","article-title":"Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma","volume":"92","author":"Sudo","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2022.109073_b0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-016-0279-9","article-title":"Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives","volume":"9","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109073_b0220","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.intimp.2022.109073_b0225","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.intimp.2022.109073_b0230","first-page":"E3796","article-title":"Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFalpha-mediated inflammation and apoptosis","volume":"114","author":"Liu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.intimp.2022.109073_b0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.archoralbio.2017.10.004","article-title":"EZH2 regulates dental pulp inflammation by direct effect on inflammatory factors","volume":"85","author":"Hui","year":"2018","journal-title":"Arch. Oral Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109073_b0240","first-page":"55","article-title":"Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation. Cell Mol","volume":"7","author":"Bamidele","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2022.109073_b0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fendo.2018.00121","article-title":"The Association of Sjogren Syndrome and Autoimmune Thyroid Disorders","volume":"9","author":"Baldini","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.intimp.2022.109073_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.836102","article-title":"Case Report: Onset of Type 1 Diabetes Mellitus in a Patient With Ulcerative Colitis and Sjogren's Syndrome Under Euthyroid Hashimoto's Thyroiditis","volume":"13","author":"Takahashi","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:00:46Z","timestamp":1761588046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922005574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":50,"alternative-id":["S1567576922005574"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109073","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting EZH2 prevents the occurrence and mitigates the development of Sj\u00f6gren's syndrome in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109073"}}